On May 12, 2026, the U.S. Food and Drug Administration (FDA) officially issued the revised Digital Labeling Compliance Guidance, for the first time designating corporate official websites as statutory labeling carriers, and setting out clear digital performance requirements for Chinese suppliers in specific product categories exporting to the United States. This policy directly affects the export ecosystem to the U.S. in highly regulated sectors such as food and medical devices, with the core shift being the extension of traditional paper/packaging labeling obligations to the technical capabilities of online platforms, marking an upgrade in regulatory logic from ‘product compliance’ to ‘full-chain digital trustworthiness’.

Event Overview

On May 12, 2026, the U.S. FDA officially released the revised Digital Labeling Compliance Guidance, mandating that from January 2027 onward, all suppliers exporting Class II and above medical devices, infant food, and dietary supplements to the United States must provide bilingual electronic instructions in English+Spanish on their corporate official websites, and support API integration with the FDA UDI (Unique Device Identification) and FSMA (Food Safety Modernization Act) systems to enable real-time batch-level traceability. This requirement does not replace existing packaging labels, but constitutes an independent compliance element; failure to comply may result in import customs clearance delays, escalated FDA on-site inspections, or the risk of importer rejection.

Which Sub-Sectors Will Be Affected

Direct trading enterprises: As the “Responsible Party” recognized by the FDA, they must assume primary responsibility for labeling content on their official websites. The impact is reflected in: ① official websites must complete the structured deployment and version management of bilingual instructions; ② API services must be developed in-house or procured to connect with FDA systems, with long technical validation cycles; ③ importers have already begun incorporating official website traceability capabilities into supplier admission assessments, directly affecting order acquisition.

Raw material sourcing enterprises: Although not directly registered with the FDA, if the raw materials they supply are used in regulated end products (such as infant formula base powder or sterile medical dressing substrates), they must provide downstream manufacturers with raw material batch data that can be embedded into traceability systems. The impact is reflected in: ① existing batch record formats (such as Excel ledgers) no longer meet API direct-connection requirements; ② a data collaboration mechanism with the manufacturing side must be established, otherwise traceability gaps in the end product will occur.

Processing and manufacturing enterprises: As the source of UDI/FSMA data, they undertake the triple tasks of batch number generation, code assignment, and instruction association. The impact is reflected in: ① existing MES/ERP systems generally lack external API modules, making retrofitting costly; ② instruction content must be dynamically bound to each batch (for example, different production dates corresponding to different allergen statements), which static webpages cannot support; ③ bilingual instructions require professional medical translation + localization adaptation, which cannot be covered by simple machine translation.

Supply chain service enterprises: Including cross-border compliance consulting, digital labeling SaaS providers, API integrators, etc. The impact is reflected in: ① service demand is shifting from “single-point certification guidance” to full-stack delivery of “official website-system-data”; ② providers need composite capabilities such as FDA UDI database parsing, Spanish medical terminology libraries, and FSMA Section 204 data mapping; ③ if small and medium-sized service providers only offer template-based website building, it will be difficult for them to pass importers’ technical due diligence.

Key Focus Areas and Response Measures for Relevant Enterprises or Practitioners

Confirm whether your products fall within the mandatory scope

Not all exported food/devices are applicable——only Class II and above medical devices in FDA classifications (including some home-use testing devices), infant food defined under CFR Title 21 Part 106, and dietary supplements regulated under the Dietary Supplement Health and Education Act (DSHEA). Enterprises must cross-check according to FDA product codes (Product Code) and classification databases to avoid misjudgment that unnecessarily expands the scope of rectification.

Differentiate between the two levels of “official website display” and “compliance interface”

Putting bilingual instructions online is only a surface-level action; the key is that the API interface must pass validation in FDA-designated test environments (such as FDA’s UDI Test System), and continuous availability of over 99.5% must be ensured. From the analysis, most Chinese official websites currently only satisfy front-end display requirements and have not deployed data middleware compliant with HL7/FHIR standards, leaving substantive compliance gaps.

Establish a cross-departmental collaboration mechanism

Instruction content involves regulatory affairs (compliance), medical affairs (clinical statements), IT departments (API development), and marketing departments (multilingual copywriting). A dedicated project team should be established and data ownership clearly defined. Observationally, some leading enterprises have already incorporated the “digital labeling responsible person” into quality management system (QMS) documentation, granting them sign-off authority equivalent to QA.

Editor’s View / Industry Observation

What is currently more noteworthy is that the FDA has not set any transition exemption period this time, and has directly linked official website traceability capabilities with FSMA Section 204 “critical tracking records”—this means the requirement is not an isolated labeling policy, but rather a technical support point embedded in the U.S. end-to-end food/device safety early warning system. It is more appropriately understood as: the FDA is using digital infrastructure to force the global supply chain to improve data granularity and system interoperability. For Chinese enterprises, the challenge lies not in translation or website building, but in breaking the long-standing separation among “business systems-compliance systems-marketing systems”.

Conclusion

The essence of this guidance is a shift in the regulatory paradigm: from verifying “whether the product is qualified” to verifying “whether the enterprise has trustworthy digital performance capabilities”. In the short term, it increases compliance costs; in the medium and long term, enterprises that take the lead in building official website traceability capabilities will gain structural advantages in importers’ preferred partner lists, intelligent sorting in overseas warehouses, and even FDA fast-track review channels. The rational conclusion from observation is: this is not a one-time response task, but an essential milestone in the globalization of digital infrastructure for Chinese enterprises.

Information Source Notes

Official sources: the Digital Labeling Compliance Guidance (Revision #3, May 2026), document number FDA-2026-DLG-001, published on the official U.S. FDA website; supporting technical document API Integration Specifications for Real-Time Batch Traceability v1.2. Items for continued observation: whether the FDA will release implementation FAQs for non-native English-speaking enterprises in Q4 2026; and whether the EU EMA and Japan PMDA will follow up with similar digital labeling requirements.